Lobular breast cancer uk

Working together, we can all live well

www.lobularbreastcancer.org.uk



ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Charitable incorporated organisation registration number: CE023524

Charity registration number: 1191402

LOBULAR BREAST CANCER UK
ANNUAL REPORT AND ACCOUNTS 2025

Contents

	Page No.
Welcome from our Co-Chairs and Interim CEO	1
Unlocking the challenges of Lobular Breast Cancer	3
Our Year of Impact	4
Our Purpose, Vision and Values	5
Our Strategic Objectives	6
Trustees Report	7
Chartered Accountants' report	23
Statement of financial activities	24
Balance sheet	25
Notes to the Financial Statements	26
Legal and Administrative Details	33

Lobular breast cancer uk

Welcome from Emma Amos and Anne Carey, our Co-Chairs

2025 has been an exciting and busy year for us at Lobular Breast Cancer UK.

Demand for our services and reliable, trusted information and support about Lobular Breast Cancer continue to grow. We provide direct services to people with a diagnosis of Lobular Breast Cancer and their families through email and social media communications, our website and online resources and patient meet ups, both in person and digitally.

Collaboration and co-creation remain at the heart of our work and we have strengthened partnerships with key organisations including Breast Cancer Now, De Montfort University, the European Lobular Breast Cancer Advocates and European Lobular Breast Cancer Consortium, Future Dreams, Lobular Breast Cancer Alliance, and collaborations with clinicians and researchers across the UK and globally on much needed research into this distinct disease.

Our Board joins us in thanking our Patrons Josie Lloyd and Dame Martina Milburn; our Scientific and Medical Advisory Group; our families, friends, supporters, partners and anyone who has raised funds for our work.

Recognising the need to strengthen our Board further, we launched a Trustee recruitment campaign to improve our governance and bring more resource into the charity. We welcomed 3 new Trustees to the Board in 2025. Thank you Andrea Lener, Susan Barton and Lesley Goodburn for your commitment to Lobular Breast Cancer UK.

We want to thank our existing Trustees Professor Sara MacLennan, Elaine Nangle, Hannah Philips, Dr Jane Sedcole and our Founder non-Trustee members Dr Helen Coulthard, Darlaine Honey, and Lorna McHattie, for their continued commitment, energy and passion towards developing our charity, whilst also living with a Lobular Breast Cancer diagnosis.

The Board would also like to express our sincere gratitude to our Founder Claire Turner for her unwavering dedication and inspiration. Since stepping down as Chair in 2024, and taking on the role of Interim Chief Executive Officer, she has continued to move the charity forward, forging links with national and international organisations, working to increase the awareness of Lobular Breast Cancer among health care professionals, to provide more information and support for patients and their families facing a Lobular Breast Cancer diagnosis.



2026 will be a year of transformation for us at LBCUK as we begin work to make real clinical changes, launching our *Distinctly Lobular* campaign to ensure that Lobular is recognised in the UK's treatment guidelines as a distinct disease.

Finally, we want to remember our friend and founder member Ruth Warden who died this year of Lobular Breast Cancer. Ruth was an inspirational colleague and friend to everyone at LBCUK. She was passionate, wise, and had a warmth that communicated itself to everyone she came into contact with.

Any discussions concerning the tone of our website and our values at LBCUK are always prefaced with 'what would Ruth say?' She will be missed greatly by everyone at LBCUK .

We also want to remember all those who died this year of Lobular Breast Cancer. One person is too many. Our thoughts and love extend to their families and friends.

We commit to working together to ensure everyone with a Lobular diagnosis lives and lives well.

Welcome from Claire Turner, our Interim-CEO

2025 has been a real year of changes for our charity.

Stepping into a part-time role as Interim-CEO of the charity was never my intention when initially setting up the charity as volunteer Chair. After a career of working in charities, it was never a path I envisaged with LBCUK, but the need and demand for what we do requires a consistent and sustainable resource in the organisation. I hope that I am able to best serve all of us who had had a diagnosis of this distinct disease that is Lobular Breast Cancer.

We have seen rapid growth in individual requests for information and support from people diagnosed and their family and friends; research partnerships with institutions in the UK and internationally; development of new partnerships with support organisations; and have developed a core role in enhancing healthcare professional education and knowledge about Lobular.


As always we strive to do better and I know that there are areas that we can improve on in 2025 and beyond, especially in the provision of support and information for people with a metastatic Lobular diagnosis.

I want to say a huge thank you to the Board and founder members for their commitment and dedication to driving the charity forward; to Kirsty Marrins whose skill and communication abilities have transformed our communications; to all of our partners who it would not be possible to do what we do without their collaboration and relationships; and to everyone who has supported the charity in any way, I personally say thank you.

We remain an organisation 100% led by women who have had an experience of Lobular Breast Cancer with our core value of "the patient is always first" at the heart of all we do.

As we move into 2026, I look am excited about the growth in Lobular understanding and research we are seeing. There is so much to do, but the networks and collaborations both here in the UK and around the world continue to grow. I commit to bringing my best self to our work at LBCUK and leading through our charity values. It is only by working together, can we all live well.

Unlocking the challenges of Lobular Breast Cancer



- Lobular Breast Cancer is **the second most common type of breast cancer representing 15% of all breast cancer diagnoses**.
- Around **8,400 people are diagnosed with Lobular Breast Cancer** in the UK each year.
- Due to its unique growth pattern, more like a spider's web, **Lobular Breast Cancer rarely forms a lump**.
- Lobular Breast Cancer **can be harder to detect** through self-examination and standard imaging methods for both primary (early) breast cancer and in metastatic or secondary breast cancer.
- If Lobular Breast Cancer spreads, **it can occur in different parts of the body** from the more common ductal breast cancer, such as the ovaries and womb, stomach and intestine, the lining of organs and the eyes.
- Lobular Breast Cancer has **the potential to return many years after an initial primary breast cancer diagnosis**.
- We **need increased information and knowledge about Lobular Breast Cancer** across the general public and healthcare professionals, and **more research**.
- Current UK treatment guidelines do not recognise Lobular as a distinct disease.

Data from National Disease Registration Service NHS England 2023

A Year of Impact

Feedback from people using our services shows that *:

89%
said that it increased their knowledge and understanding of Lobular Breast Cancer

65%
said that it reduced their sense of isolation following a Lobular Breast Cancer diagnosis

72%
said that it increased their ability to advocate for themselves and have better, informed conversations with their medical team

50%
said it helped to reduce feelings of fear following a Lobular Breast Cancer diagnosis

"I think you are amazing and are doing a fantastic job in difficult circumstances."
Participant at one of our Lobular Breast Cancer support sessions

"Your work is literally saving lives, thank you"
Feedback from someone who used our information to speak with their oncologist

"Excellent presentation and increased my understanding of Lobular Breast Cancer"
Healthcare Professional participant at Lobular training workshop

Our Purpose, Vision and Values

OUR PURPOSE

Working together, we can all live well.

OUR VISION

Lobular Breast Cancer is understood comprehensively, diagnosed effectively, treated appropriately, and patients have access to support across the UK.

OUR VALUES

- The patient is always first.
- We are bold and courageous in speaking up for ourselves and anyone affected by Lobular Breast Cancer.
- We commit to reducing the isolation and fear of a Lobular Breast Cancer diagnosis.
- We are evidence based in all our communications and information.
- We act compassionately towards everyone, recognising and accepting our different experiences and beliefs, and treating each other with care, consideration and respect.
- We are stronger together, collaborating and sharing learning with all our stakeholders.



Our Strategic Objectives

AIM 1: INFORMATION & EDUCATION

We advance knowledge and understanding of Lobular Breast Cancer by providing appropriate and timely information for the public, clinicians, health professionals, researchers, relevant charities and the media..

AIM 2: POLICY & TREATMENT GUIDELINES

We work with our partners to develop appropriate policy and treatment guidelines across the UK, recognising the different health systems across the four countries of the UK.

AIM 3: RESEARCH

We work with patients, researchers and health professionals in the UK and internationally to ensure that research and trials conducted for Lobular Breast Cancer meet the needs of patients, and we collaborate on the raising of funds for research initiatives focused on Lobular Breast Cancer.

AIM 4: SUPPORT

We provide routes to appropriate support and connection for patients, reducing the isolation and fear of a Lobular Breast Cancer diagnosis.

AIM 5: OUR IMPACT

We continue to build LBCUK as an effective, professional and sustainable independent charity, increasing our impact.

LOBULAR BREAST CANCER UK
ANNUAL REPORT & ACCOUNTS 2025

The Trustees have pleasure in presenting their report and the financial statements of the Charity for the year ended 31 December 2025.

LBCUK's CHARITABLE OBJECTS

The object of the CIO is to preserve and protect the health and wellbeing of people in the UK through the provision of education, training, support with trials and research, lobbying and advocacy around Lobular Breast Cancer.

LOBULAR BREAST CANCER UK

Lobular Breast Cancer UK (LBCUK) is a patient-led voluntary charity registered as a Charitable Incorporated Organisation on 22 September 2020 and launched on 22 September 2021.

We established in response to a lack of information and appropriate treatments for patients diagnosed with Lobular Breast Cancer.

Lobular Breast Cancer is a sub-type of breast cancer that makes up 15% of all breast cancers diagnosed and is the second most common form of the disease.

The key challenges we face include:

- Lobular is a distinct disease that behaves differently from other breast cancers. However current UK guidelines, and many clinicians, do not recognise it as a distinct disease;
- Lobular tumours grow like a spider's web in straight lines rarely forming a lump. This can make it hard to see on scans. As a result, we are often diagnosed at a more advanced stage of the disease and with larger tumours;
- a lack of understanding how Lobular grows, spreads, and responds to treatment. It is an under-researched and under-funded disease;
- ensuring that everyone is told that they have Lobular Breast Cancer, not simply breast cancer. It is impossible to make the best treatment decisions if you do not know that you have Lobular;
- there are no treatments specifically targeted for Lobular;
- more research is needed into the psychological impacts of a Lobular diagnosis.

We are 100% led by people who have had a Lobular Breast Cancer diagnosis, ensuring that people with lived experience always remain at the forefront of our work.

INCREASING INFORMATION and KNOWLEDGE


Increasing knowledge about Lobular Breast Cancer for the public

During 2025, we again saw **a huge increase in the need for evidence-based, trusted and factualy accurate information and materials about Lobular Breast Cancer**. There were **over 1,500 downloads of Lobular information materials** from our website during the year.

We want to say a huge thank you to **everyone who generously shared your own experiences of being affected by Lobular Breast Cancer**. Your stories help other people and raise knowledge and understanding of this distinct disease.



We were **one of seven winning recipients of a Costello Medical, medical communications speciaists, Women's Health Award**. Working with their specialist analysts and designers, we received pro bono (free) support to produce **a new accessible and evidence-based information leaflet about Lobular Breast Cancer**.



The leaflet was co-created with women who have had a Lobular Breast Cancer diagnosis and will be available for distribution in 2026.

Increasing Healthcare Professionals' knowledge

During 2025 we worked to increase the knowledge and understanding of Lobular Breast Cancer amongst Healthcare Professionals through the provision of online webinars and training, and in-person presentations.

Following previous training with Breast Cancer Now's Helpline Breast Care Nurses, we **produced a Lobular webinar with Breast Cancer Now aimed at Healthcare Professionals**.

This educational resource is available on their website and provides CPD points for participants. **It has consistenly been in the top 5 of all of Breast Cancer Now's training webinars and was their second most popular educational webinar during 2025**.

Feedback from Healthcare Professional webinar participants:

"Excellent presentation and increased my understanding of Lobular Breast Cancer"

"I'll use this in my discussions and support of patients, family and colleagues"

"Really helpful research-based information in an easy to listen to and informative way"

Our **Lobular *GP Working Group* launched in 2025.** Following meetings with a number of GPs and Practice Nurses who had had their own Lobular diagnosis, but knew nothing about this distinct type of breast cancer. The Group involves GPs and Practice Nurses with lived experience of Lobular and aims to increase knowledge about Lobular and enhance patient experience following a Lobular diagnosis in primary care.

The Group's first action was a multi-page headline feature in the Sunday Mail's Health pages followed by **the first UK-wide survey to understand people's experiences with their GPs during a Lobular Breast Cancer diagnosis**. The results from this survey will be used to guide the work of the Group and develop education programmes in primary healthcare.

In March, Emma Amos, LBCUK Co-Chair and Claire Turner, **attended Barts Hospital's annual Breast Health Day**.



Claire & Emma with Vas Angelis, Barts Hospital Consultant Oncologist

They **presented to the entire Breast Care team about Lobular Breast Cancer**, how a diagnosis can impact us both physically and mentally and how healthcare professionals can best support their patients.

#22ADayUK campaign



Our #22ADayUK campaign, first launched in 2022 after we identified this statistic, continued representing the 22 people diagnosed with Lobular Breast Cancer every day in the UK. A big thank you to all our groups for taking part and increasing knowledge about Lobular.

Increasing knowledge through media



Gaining media coverage is a particular challenge for us as a charity. We don't currently have the in-house experience or resource to support on-going media consultants.

Darlaine Honey, one of our LBCUK founders is excellent at reaching out to media and secured an interview with Naga Munchetty for *That Time of the Month*, BBC 5 Live. Her experience of a Lobular Breast Cancer diagnosis was also featured in *Glamour* magazine.

INCREASING SUPPORT FOR PEOPLE DIAGNOSED WITH LOBULAR BREAST CANCER

As a charity, we want to avoid duplication of existing services and recognise that we do not have the capacity or training to provide individual and focused support for Lobular patients. Our strategy focuses on ensuring professional breast cancer support services are up to date with the latest Lobular information and research, and their services can respond to the specific needs of Lobular patients. We regularly link to the resources of our international partner **Lobular Breast Cancer Alliance,** for example with their research and trials database.

Online and in-person support







In partnership with Future Dreams House, London we again delivered a series of in-person and online patient meetups enabling **over 70 women with a Lobular Breast Cancer diagnosis to connect, share experiences and learn more** about Lobular Breast Cancer.

> *"It was so wonderful to meet someone else with a Lobular diagnosis"*
>
> Future Dreams participant

We recognise the need and demand for more support services and opportunities to bring the Lobular community together and we will be exploring ways to improve on this for 2026.

Our monitoring **MRI template letter continues to be downloaded from our website to support women's requests for more appropriate post-diagnosis monitoring, and monitoring they feel confident in**. The letter has been successful in enabling many women to access supplementary imaging following primary Lobular Breast Cancer.

We responded to **over 210 individual questions and concerns about Lobular from women diagnosed with this disease and their family and friends** through our email, social media and direct mail.

Over 24,000 individuals accessed our website to increase their knowledge of Lobular Breast Cancer and **1,262 individuals downloaded evidence-based supportive materials** from our website.

Social media engagement

Our social media provides a trusted and evidence-based source of information for the public.

During the first half of the year, we saw real growth in our social media followers across all platforms, especially on Facebook with a **40% increase in followers** and this continued into the latter half of the year with a **65% increase in followers**. Importantly our **engagement rate grew from 4% to 9%,** as our audience became more active rather than simply passively reading our content.

INCREASING RESEARCH

We developed new and enhanced our on-going relationships with the leading Lobular healthcare professionals, researchers and research institutes across the UK and internationally.

We continued facilitating the **Lobular Breast Cancer UK Network** to build collaboration and relationships between researchers, health professionals and patient advocates from across the UK. By bringing together a diverse range of individuals we plan to action real change in knowledge, understanding and treatment of Lobular across the four countries of the UK.


Increasing Lobular Breast Cancer Data and Knowledge

It is only through capturing and using real world data can we fully understand the impact of Lobular Breast Cancer on our society and what We need to do to make changes.

Partnering with the National Disease Registration Service, **we produced the first data about Lobular Breast Cancer from NHS England**.

The information includes how many people are diagnosed, age and stage at diagnosis, ethnicity, sex, and Cancer Alliance individuals are treated in.

Our next steps in 2026 are obtaining the data for the other three countries in the UK.



Our Interim-CEO also sits on the National Audit for Primary Breast Cancer and has been pushing for a breakdown of data into Ductal (or Non-Specific Type) and Lobular. Whilst this did not happen in 2025, we will continue to drive for this change in the 2026 State of the National report.

Increasing Lobular Research funding

NIHR | National Institute for Health and Care Research

Invasive lobular carcinoma (lobular breast cancer) highlight notice

Working with the Government's National Institute for Health and Care Research (NIHR) we were successful in the development and launch of a Lobular highlight notice that was launched in December 2025. This notice is focused on the development of clinical studies for Lobular to build on existing knowledge about this distinct disease's basic biology from the past 10-plus years of Lobular research.

Highlight notices focus on specific diseases and provide additional support and encouragement for researchers and research institutions to submit funding bids to these Government schemes.

We hope that we see successful Lobular research applications leading into 2026 and are working with the UK"s Lobular researchers, healthcare professionals and research institutions to develop proposals.

Increasing Research Collaboration & Partnerships



Our Research Partnership Days help to build an understanding between healthcare professionals, researchers and people who have been diagnosed with Lobular Breast Cancer. We delivered two events in 2025 in partnership with the University of Manchester and Manchester Breast Centre in January and King's College London, the Institute of Cancer Research, Royal Marsden hospital and St George's NHS Trust in October.

These days help to build understanding about what research is being conducted into Lobular in the UK and incorporate the patient experience into these research ideas.

"Thank you for today, it was absolutely amazing. It really put the human face to Lobular research"

Participant in Research Partnership Day

As the **facilitator of the UK Lobular Research Network**, we bring together researchers, healthcare professionals and institutions to ensure that there is collaboration, shared learning and opportunities to collaborate on the development of grant proposals. **Over 30 individuals are now involved in Network meetings**.

Our Interim-CEO continues her voluntary role as UK Patient Advocate with the European Lobular Breast Cancer Consortium (ELBCC), the European Lobular Breast Cancer Advocates, GlobMob, the international Lobular collaborative research network and the Planning Committee for the International ILC Symposium.

Increasing Research



Working with research institutions and driving the increase in research into Lobular remained a key and growing focus for us throughout the year.

We continued to work as **partner patient advocacy charity** with UK and international institutions including: **De Montfort University, City St George's Hospital, KU Leuven Belgium, the Institute of Cancer Research, the University of Aberdeen, University of Manchester, UMC Utrecht the Netherlands, and the Royal Marsden Hospital.** We were also co-author on publications from **Manchester Breast Centre** and **Oxford Brookes University**.

We **presented to the UK Clinical Studies Group** about the need for more clinical trials into Lobular Breast Cancer; for the removal of barriers into breast cancer clinical trials for people diagnosed with Lobular; and requested the breakdown of research findings into ductal and Lobular Breast Cancer data to understand findings in the context of a Lobular diagnosis.

IMPROVING POLICY & TREATMENT GUIDELINES

Campaigning

In 2025 we became a member of *One Cancer Voice* to amplify our message and to join 60 other cancer charities calling on the government to deliver a fully-funded cancer plan.

We especially called for:

- Lobular Breast Cancer to be recognised as a distinct disease in UK treatment guidelines;
- better screening and monitoring programmes in both primary and metastatic disease;
- for more clinical trials and Lobular specific data.



Our **Interim-CEO continues to sit on the Patient and Public Forum for the National Institute for Health and Care Excellence (NICE)**. NICE is the body that sets the treatment guidelines for England and Wales.

This is a new area of work for us at LBCUK. We have learnt so much from working alongside more experienced cancer charities and colleagues.

INCOME GENERATION

During 2025 we chose not to deliver any official LBCUK fundraising events in recognition of our need to spend our reserves for public benefit, rather than building them to inappropriate levels.

Individuals and groups impacted by Lobular Breast Cancer continued to support our work and we want to extend a huge thank you to everyone who has raised funds for us throughout the year. Every invaluable penny raised is spent on the delivery of our work and enables to continue to improve information, knowledge and research for everyone diagnosed with Lobular Breast Cancer.



We have developed a plan to diversify our income streams across trust and foundation grants, community fundraising, partnerships and research advocacy fees. This will enable us to become more sustainable, resilient and to meet projected increased expenditure during 2026 to meet the growing demand for our services.

FINANCIAL REVIEW

As a primarily volunteer run charity, we have few overheads.

Our annual budgets are approved and monitored by the Board at each meeting. Any variances from the proposed budget are highlighted and discussed at the meetings.

In the opinions of the Trustees, the Charitable Company's assets are sufficient to fulfil the obligations of the Charity.

RESERVES POLICY

Our Reserves Policy aims for a target of between three – six months operational expenditure with a target of £20,000. The testing of much-needed Interim-CEO and

freelance social media support to meet the increasing and ever-growing demand for our services may require a review again of Reserves during 2026.

At the balance sheet date the charity held total funds of £19,743 (2024: £31,676) of which £510 (2024: £0) were held in restricted funds leaving £19,233 (2024: £0) in free reserves.

We feel this is a much more responsible level of reserves for the size of our current expenditure, but also recognise that expenditure is due to rise during 2026 as demand for our services continues to grow and new partnerships are formed.

REVIEW OF RISKS

The Trustees have considered the major risks facing the charity and have put in place appropriate policies and procedures to mitigate them.

The primary risk to the charity is the growing demand for our services and the lack of personnel resource to meet this demand. A Trustee recruitment process took place in early 2025 to fill identified gaps on the Board in policy change and campaigning, digital communications and digital engagement. We are now a Board of 9, all with lived experience of a Lobular diagnosis, and welcomed Andrea Lener, Hannah Phillips and Susan Barton as Trustees.

In addition, we have begun testing the appointment of an Interim-CEO for the charity starting from 1 December 2024 for an initial 12 months and working with a freelance digital communications specialist two days a month.

2026 PLANS

AIM 1: INFORMATION & KNOWLEDGE: we advance education and understanding of Lobular Breast Cancer by providing information for the public, clinicians, health professionals, researchers, relevant charities and the media.

AIM 2: SUPPORT: we provide routes to appropriate support and connection for patients, reducing the isolation and fear of a Lobular Breast Cancer diagnosis.

AIM 3: RESEARCH: we will work with patients, clinicians and health professionals to ensure that research and trials conducted for Lobular Breast Cancer meet the needs of patients, and we will raise funds for research projects**.**

AIM 4: POLICY & TREATMENT GUIDELINES: we will work with partners to develop appropriate policy and treatment guidelines across the UK, recognising the different health systems across the four countries.

AIM 5: OUR IMPACT: we continue to build LBCUK as an effective, professional and sustainable independent charity, increasing our impact.

A key focus for 2026 and beyond is the delivery of a new campaign to gain recognition guidelines of Lobular Breast Cancer/Invasive Lobular Carcinoma (ILC) as a distinct disease in the UK Breast Cancer Treatment Guidelines. It is a disease that requires different guidelines in key areas of treatment.

We will continue to build stronger collaborative relationships across the UK and internationally with other Lobular specific and breast cancer charities, especially developing the collaborative relationship we have with Breast Cancer Now.

Ensuring the necessary support is in place for Lobular patients is key for 2026, and we will be building on our work with Future Dreams House to establish regular in person and online meet up workshops for people to come together, especially in areas facing greater health inequalities.

The development of more research into this distinct disease is essential. We will deliver further Lobular Research Partnership Days in 2026 to drive forward interest in Lobular research with Early Career Researchers and to develop more individuals who can ensure that the patient voice is included in research.

STRUCTURE GOVERNANCE & MANAGEMENT

GOVERNING DOCUMENT

The Charity is a Charitable Incorporated Organisation and is governed by its Foundation CIO Constitution. It is registered as a CIO with the Charity Commission for England & Wales.

TRUSTEE INDUCTION, RECRUITMENT & TRAINING

The Trustees are collectively known as the Board. Trustees are appointed by invitation from the existing Trustees and through an open recruitment process. Invited potential Trustees are requested to either provide a CV and covering letter/three minute short film for consideration by the Board or to participate in an on-going formal open recruitment process. All potential Trustees are interviewed by a panel of at least two current Trustees. An appointment recommendation is made to the Board only if an individual's values align with our Charity values and they bring the requisite experience needed by the Charity.

New Trustees are provided with a copy of the Charity Commission's leaflet for new Trustees, 'The Essential Trustee: what you need to know, what you need to do' (CC3), a copy of our Constitution, a copy of the Charity Governance Code, recent Board minutes and latest Annual Report and Accounts. They also receive a briefing and annual reviews with the current Co-Chairs.

ORGANISATION

The Charity is governed by the Board and managed by the Charity's Trustees and two voluntary Founders. The Trustees who have acted during the year are listed above. One of the listed Trustees was a Founding Trustee of the charity.

Trustees meet approximately 4 - 5 times a year to discuss and agree on matters of charity governance, policy and strategy. Further ad hoc meetings are organised as required to address specific issues. Trustees develop strategies to increase charity awareness, widen reach across our stakeholders and build the sustainability of this new and growing organisation.

These meetings also include budget reports and cash flow. Any changes in strategy are discussed, amended and when agreed, adopted as written charity policy by Trustees.

Where risks are identified, steps are taken to mitigate these risks, including reference to how the charity has met its charitable aims in the advancement of education, training, support, research and advocacy. Any actions taken are then reported on and reviewed at subsequent meetings.

The implementation of policies and strategies is delivered operationally by the Trustees and the four volunteer Founder Members. To ensure that our activities are evidence based and reflect the latest scientific knowledge about Lobular Breast Cancer, we have a Scientific and Medical Advisory Group involving six respected healthcare professionals and researchers in the field of Lobular Breast Cancer.

We have no premises and operate across the UK.

All Trustees and appropriate volunteers are DBS checked and participate in relevant training programmes.

RESPONSIBILITIES OF THE TRUSTEES

Under charity law, the Trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the income and expenditure of the Charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" has been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008 and the provisions of the CIO constitution. It is also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity and signed on its behalf by



Emma Amos
Co-Chair of Trustees
28 October 2026

Independent examiner's report to the Trustees of Lobular Breast Cancer UK

I report to the Charity Trustees on my examination of the accounts of the *Lobular Breast Cancer UK* ('the Charity') for the year ended 31 December 2025.

Responsibilities and basis of report

As the charity trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 (the Act). I report in respect of my examination of the Charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- accounting records were not kept in respect of the Charity as required by section 130 of the Act; or
- the accounts do not accord with those records; or
- the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a "true and fair view" which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Company's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Company and the Company's Trustees as a body,
for my work or for this report.

Signed: Date: 28 October 2026



Joanne Harding, FCCA

Menzies LLP
One Express
1 George Leigh Street
Manchester, M4 5DL

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Statement of Financial Activities
(Including Income and Expenditure Account)
FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	Unrestricted funds 2025 £	Restricted funds 2025 £	Total funds 2025 £	*Total funds 2024 £*
Income from:					
Donations and legacies	3	**38,692**	**2,935**	**41,627**	*14,684*
Total income		**38,692**	**2,935**	**41,627**	*14,684*
Expenditure on:					
Raising funds	4	**1,415**	-	**1,415**	*1,572*
Charitable activities	5	**49,720**	**2,425**	**52,145**	*18,893*
Total expenditure		**51,135**	**2,425**	**53,560**	*20,465*
Net movement in funds		**(12,443)**	**510**	**(11,933)**	*(5,781)*
Reconciliation of funds					
Total funds brought forward		**31,676**	**-**	**31,676**	*37,457*
Net movement in funds		**(12,443)**	**510**	**(11,933)**	(5,781)
Total funds carried forward		**19,233**	**510**	**19,743**	31,676

The statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 26 to 32 form part of these financial statements.

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
(Registration number: CE023524)
Balance Sheet
AS AT 31 DECEMBER 2025


	Note	2025 £		*2024 £*	
Fixed assets			--		--
Current assets					
Cash at bank and in hand		**22,643**		*32,426*	
		22,643		*32,426*	
Current Liabilities					
Creditors: Amounts falling due within one year	10	**(2,900)**		*(750)*	
Net current assets			**19,743**		*31,676*
Total assets less current liabilities			**19,743**		*31,676*
Net assets excluding pension asset			**19,743**		*31,676*
Total net assets			**19,743**		*31,676*
Charity funds					
Restricted funds	11		**510**		--
Unrestricted funds	11		**19,233**		*31,676*
Total funds			**19,233**		*31,676*

The members have not required the Charity to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies' regime.

The financial statements were approved by the trustees, and authorised for issue on 28 October 2026 and signed on their behalf by:



Emma Amos
Co-Chair

LOBULAR BREAST CANCER UK
(A Charitable Incorporated Organisation)
Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2025

1. General Information

The Charity is a Charitable Incorporated Organisation, incorporated in England and Wales.

The address of its registered office is:

Piccadilly Business Centre
Unit C Aldow Enterprise Park
Manchester M12 6AE

2. Accounting Policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) – Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Lobular Breast Cancer UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Income

All income is recognised once the Company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Company to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charities' objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

2. Accounting Policies (continued)

2.4 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.5 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

2.6 Financial Instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.6 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

3. Income from donations and legacies

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total Funds 2025 £	*Total funds 2024 £*
Donations	38,692	2,935	**41,627**	*14,684*
		-		
Total 2024	*14,684*	*-*	*14,684*	
	-	-	-	-

4 Expenditure on raising funds

Costs of raising voluntary income

	Unrestricted funds 2025 £	Total funds 2025 £	*Total funds 2024 £*
Online platform fees	455	**455**	-
London Marathon fees	960	**960**	*1,572*
	1,415	**1,415**	*1,572*
Total 2024	*1,572*	*1,572*	

5 Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £	*Total 2024 £*
Research and patient advocacy	49,720	2,425-	52,145	*18,893*
Total 2024	*18,893*	-	*18,893*	

6 Analysis of expenditure by activities

	Activities undertaken directly 2025 £	Support costs 2025 £	Total funds 2025 £	*Total funds 2024 £*
Research and patient advocacy	48,443	3,702	**52,145**	*18,893*
		-	-	-
Totals 2024	*10,201*	*8,692*	*18,893*	

6 Analysis of expenditure by activities (continued)

Analysis of support costs

	Activities 2025 £	Total funds 2025 £	Total funds 2024 £
Office costs	1,872	1,872	7,942
Accountancy fees	1,830	1,830	750
	3,702	3,702	8,692
Total 2024	*8,692*	*8,692*	

7 Independents Examiner's Renumeration

	2025 £	2024 £
Fee payable to the Charity's independent examiner for the independent examination of the Charity's accounts	*750*	-
Fee payable to the Charity's independent examiner in respect of: All others services not included above	*750*	-

8 Trustee's renumeration and expenses

During the year, no Trustees received any remuneration or other benefits (*2024 - £NIL*).

During the year ended 31 December 2025, no Trustee expenses have been incurred (*2024 - £NIL*)

9 Key management personnel

The key management personnel of the charity comprise the Interim-Chief Executive Officer and the trustees.

During the year, the Interim Chief Executive Officer provided services to the charity on a self-employed basis. Fees of £30,625 (*2024 - £NIL*) were payable in respect of these services.

10 Creditors: amounts falling due within one year

	2025 £	*2024 £*
Accruals and deferred income	2,900	*750*

11 Statement of funds

Statement of funds – current year

	Balance at 1 January 2025 £	Income £	Expenditure £	Balance at 31 December 2025 £
Unrestricted funds				
General Funds – all funds	**31,676**	**38,692**	**(51,135)**	**19,233**
Restricted funds				**-**
ELBCA Leuven	**-**	**2,935**	**(2,425)**	**510**
Total funds	**31,676**	**41,627**	**(53,560)**	**19,743**

Statement of funds – prior year

	Balance at 1 January 2024 £	*Income £*	*Expenditure £*	*Balance at 31 December 2024 £*
Unrestricted funds				
General Funds – all funds	*31,610*	*14,684*	*(14,618)*	*31,676*
Restricted funds				
Restricted Funds – all funds	*5,847*	*-*	*(5,847)*	*-*
Total funds	*37,457*	*14,684*	*(20,465)*	*31,676*

12 Statement of funds

Summary of funds – current year

	Balance at 1 January 2025 £	Income £	Expenditure £	Balance at 31 December 2025 £
Unrestricted funds				
General Funds – all funds	**31,676**	**38,692**	**(51,135)**	**19,233**
Restricted funds				**-**
ELBCA Leuven	**-**	**2,935**	**(2,425)**	**510**
Total funds	**31,676**	**41,627**	**(53,560)**	**19,743**

Summary of funds – prior year

	Balance at 1 January 2024 £	*Income £*	*Expenditure £*	*Balance at 31 December 2024 £*
General Funds – all funds	*31,610*	*14,684*	*(14,618)*	*31,676*
Restricted funds	*5,847*	*-*	*(5,847)*	*-*
Total funds	*37,457*	*14,684*	*(20,465)*	*31,676*

13 Analysis of net assets between funds

Analysis of net assets between funds – current year

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total funds 2025 £
Current assets	22,133	510	**22,6434**
Creditors due within one year	(2,900)	-	**(2,900)**
Total net assets	19,233	510	**19,743**

Analysis of net assets between funds – prior year

	Unrestricted funds 2024 £	*Total funds 2024 £*
Current assets	*32,426*	*32,426*
Creditors due within one year	*(750)*	*(750)*
Total net assets	*31,676*	*31,676*

14 Related party transactions

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 December 2025.

Legal & Administrative Details

Registered Charity Name: Lobular Breast Cancer UK
Charity Registration: 22 September 2020

Charitable Incorporated Organisation Registration No: CE023524
Charity Registration No: 1191402
The Charity is incorporated in England and Wales

Trustees

Emma Amos
Susan Barton (joined 21 August 2025)
Anne M Carey
Lesley Goodburn (joined 21 August 2025)
Andrea Lener (joined 21 August 2025)
Professor Sara Jane MacLennan
Elaine Nangle
Hannah Jane Phillips
Dr Jane Patricia Sedcole

Patrons

Josie Lloyd
Dame Martina Milburn DCVO CBE

Scientific & Medical Advisory Group (SMAG)

- Professor Val Brunton, University of Edinburgh
- Dr Soujanya Gadde Consultant Radiologist, The Nightingale Centre Wythenshawe Hospital, Manchester
- Charlotte Milns Senior Breast Care Nurse, The Nightingale Centre, Wythenshawe Hospital, Manchester
- Dr Sankari Nagarajan, Deputy Director, Manchester Breast Centre, The University of Manchester
- Dr Alicia Okines, Medical Oncologist, Royal Marsden Hospital, London
- Professor Elinor Sawyer, Professor of Clinical Oncology and Breast Cancer Genetics King's College London & Guys & St Thomas Foundation Trust

Registered Office

Piccadilly Business Centre, Unit C Aldow Enterprise Park, Manchester M12 6AE

Accountant
Menzies LLP
One Express
1 George Leigh Street
Manchester
M4 5DL

Bankers
The Co-operative Bank
P.O. Box 250
Delf House
Southway
Skelmersdale
WN8 6WT

Email: info@lobularbreastcancer.org.uk **Website:** lobularbreastcancer.org.uk
Social Media: @LobularBCUK